876 Treatment of Nonalcoholic Steatohepatitis With Probiotics – A Proof-of-Concept Study With Serial Gut Microbiota Analysis by Ultra-Deep Sequencing

Wong, Vincent Wai‐Sun; Wong, Germaine; Tse, Chi‐Shing; Chan, H.L.-Y.

doi:10.1016/s0168-8278(11)60878-7

Cited by 8 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three RCTs assessed probiotics in NAFLD: the first, evaluating VSL3, was prematurely terminated for an increase in hepatic steatosis [103]; the others, assessing a mixture of Lactobacillus spp. plus either Bifidobacterium bifidum or Streptococcus thermophilus, found a significant improvement in MRS-assessed hepatic fat and aminotransferases, respectively [104,105].…”

Section: %) (G) Homa Index Change (%) (H) Fpg Change (%) (I) Serummentioning

confidence: 98%

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

et al. 2012

View full text Add to dashboard Cite

Aims/hypothesis Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH): NAFLD causes an increased risk of cardiovascular disease, diabetes and liverrelated complications (the latter confined to NASH). The effect of proposed treatments on liver disease, glucose metabolism and cardiovascular risk in NAFLD is unknown. We reviewed the evidence for the management of liver disease and cardiometabolic risk in NAFLD. Methods Publications through November 2011 were systematically reviewed by two authors. Outcomes evaluated though standard methods were: histological/radiological/biochemical features of NAFLD, variables of glucose metabolism and cardiovascular risk factors. Seventy-eight randomised trials were included (38 in NASH, 40 in NAFLD): 41% assessed post-treatment histology, 71% assessed glucose metabolism and 88% assessed cardiovascular risk factors. Lifestyle intervention, thiazolidinediones, metformin and antioxidants were most extensively evaluated. Results Lifestyle-induced weight loss was safe and improved cardio-metabolic risk profile; a weight loss ≥7% improved histological disease activity, but was achieved by <50%

show abstract

Section: %) (G) Homa Index Change (%) (H) Fpg Change (%) (I) Serummentioning

confidence: 98%

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Probiotics are beneficial microorganisms when ingested in specified dosages. Several studies showed that gut microbiota manipulation by probiotic supplements is associated with reduced liver damage, decreased concentrations of LPS, as well as improved aminotransferase concentrations (90)(91)(92)(93). A recent review summarized the studies that show that probiotic supplementation in animal models and human studies improve inflammatory status and clinical manifestations in NAFLD (94).…”

Section: Introductionmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet

Mokhtari

Gibson

Hekmatdoost

2017

Advances in Nutrition

138

100

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder in the world, yet the pathogenesis of the disease is not well elucidated. Due to the close anatomic and functional association between the intestinal lumen and the liver through the portal system, it is speculated that the gut microbiome may play a pivotal role in the pathogenesis of NAFLD. Furthermore, diet, which can modulate the gut microbiome and several metabolic pathways involved in NAFLD development, shows a potential tripartite relation between the gut, diet, and the liver. In this review, we summarize the current evidence that supports the association between NAFLD, the gut microbiome, and the role of diet. Adv Nutr 2017;8:240-52.

show abstract

“…Several proand prebiotics, such as VSL+3, MIYAIRI588, Bifidobacterium bifidum, and Lactobacillus plantarum, and antibiotics may have beneficial effects (143)(144)(145)(146)(147). Nonetheless, conflicting data on VSL+3 suggesting a detrimental effect on hepatic steatosis raise questions about interindividual differences in response to probiotics (148).…”

Section: Different Underlying Pathophysiologies and Therapeutic Implimentioning

confidence: 99%

Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis

et al. 2017

View full text Add to dashboard Cite

876 Treatment of Nonalcoholic Steatohepatitis With Probiotics – A Proof-of-Concept Study With Serial Gut Microbiota Analysis by Ultra-Deep Sequencing

Cited by 8 publications

References 0 publications

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet

Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis

Contact Info

Product

Resources

About